NCT06908577 - An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of Tozorakimab | Biotech Hunter

Enrollment

252

Participants

Timeline

Start Date

April 7, 2025

Primary Completion Date

November 25, 2025

Study Completion Date

November 25, 2025

Conditions

Healthy Participants

Interventions

DRUG

Tozorakimab

Tozorakimab will be administered as a single SC dose using an AI or APFS device on Day 1.

DEVICE

Autoinjector (AI) Device

AI device will be used to administer single SC dose of tozorakimab on Day 1.

DEVICE

Accessorised Prefilled Syringe (APFS) Device

APFS device will be used to administer single SC dose of tozorakimab on Day 1.

Trial Locations (4)

Research Site, Berlin

Research Site, Baltimore

Research Site, Glendale

Research Site, Harrow